Andrew Left (Citron Research) Says Mallinckrodt is WORSE than Valeant

“I think Mallinckrodt is worse (than Valeant) because they are dependent on one drug, close to let’s say 50 percent of their EBITDA, depends on what metric you want to look at, is dependent on one particular drug. Not let’s say 30 that Valeant has,” said Left.